SCHEMBL6478259

SCHEMBL6478259

CC(C)(C)OC(=O)NCCSCCC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
TSHR P16473 1/20 0.41
IDO1 P14902 2/20 0.41
CA1 P00915 4/20 0.40
CA2 P00918 4/20 0.40
CA12 O43570 3/20 0.40
CA9 Q16790 3/20 0.40
EPHX1 P07099 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 1/20 0.36
GFER P55789 1/20 0.36
CTSS P25774 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1785039 0.88 MEN1 (0.50) KMT2AMEN1GAATDP1LMNA
SCHEMBL5593747 0.85 TDP1 (0.46) KMT2AMEN1GAATDP1MAOA
SCHEMBL322326 0.85 MEN1 (0.50) KMT2AMEN1GAATDP1HSD17B10
SCHEMBL25250680 0.83 TDP1 (0.50) KMT2AMEN1GAATDP1LMNA
SCHEMBL16917207 0.83 TDP1 (0.50) KMT2AMEN1GAATDP1LMNA
SCHEMBL8438785 0.83 TDP1 (0.59) KMT2AMEN1GAATDP1LMNA
SCHEMBL156911 0.82 GAA (0.58) KMT2AMEN1GAATDP1MAOA
SCHEMBL19165152 0.81 TDP1 (0.49) KMT2AMEN1GAATDP1LMNA
SCHEMBL32688836 0.81 TDP1 (0.49) KMT2AMEN1GAATDP1LMNA
SCHEMBL10331453 0.81 TDP1 (0.49) KMT2AMEN1GAATDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933296-B2 Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors ALTANA PHARMA B.V. (NL) 2005-08-23 US disclosed
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ALTANA PHARMA B.V. (NL) 2003-10-16 US disclosed
EP-1296956-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA Pharma AG (DE) 2003-04-02 EP disclosed
WO-2001094319-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA PHARMA AG (DE) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ADRB1, ADRB2, ADRA1D KMT2A 3077/4885MEN1 3014/4885GAA 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.